PDLI adds antibiotics to antibodies

Protein Design Labs Inc. is taking advantage of basic research done by one of its scientific founders to expand its R&D pipeline beyond the company's core humanized and human antibody technology platform. PDLI announced its first partnership last week, with Eli Lilly and Co., for the microbial pathogenesis program.

PDLI hopes to diversify its portfolio with antibiotics developed using gene expression technology developed by Stanley Falkow at Stanford University. Falkow is a scientific founder of PDLI, which has become widely identified with its commanding patent estate in humanized antibodies...